Filter by:
Topic
Resource Type
Display Only
Showing 238 Results
Communicating About Comparative Effectiveness Research: A Health Affairs Symposium on the Issues
One of many issues connected with comparative effectiveness research is how the findings will be communicated, particularly if they pertain to prescription drugs and if the findings could be useful…
Principles for Planning and Conducting Comparative Effectiveness Research
A group of researchers developed a set of 13 best practice principles for comparative effectiveness research. The 13 principles were published as part of a peer-reviewed study in the September 2012…
Imputing Productivity Gains From Clinical Trials
A new study conducted by Tufts Medical Center and the National Pharmaceutical Council demonstrates a novel approach to measure productivity. The study found that therapies to treat depression yielded…
Role of Pharmaceuticals in Value-Based Healthcare: A Framework for Success
Accountable Care Organizations (ACOs) have received a great deal of attention and press through peer-reviewed articles and news stories. In an ACO, providers have at least some financial…
A Translation Table for Patient-Centered Comparative Effectiveness Research-- Guidance to Improve the Value of Research for Clinical and Health Policy Decision-Making
This collaborative project was developed by the National Pharmaceutical Council, the Center for Medical Technology Policy, and Outcome, a Quintiles Company.
Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making
In a special supplement to the May 2012 Journal of Managed Care Pharmacy, National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, takes a closer look at comparative…
The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making (2012)
The National Pharmaceutical Council conducted its second annual survey of key health care stakeholders. 95 percent of respondents said that CER was "somewhat" or "very important" to them or their…
Making Informed Decisions: Assessing the Strengths and Weaknesses of Study Designs and Analytic Methods for Comparative Effectiveness Research
The purpose of this document is to provide brief descriptions of both experimental and nonexperimental study designs and methods that may be used to address CER study questions.
Pharmaceutical Technology Assessment: Perspectives From Payers
The processes and evidence used in making pharmaceutical coverage decisions vary substantially among US health plan payers. These variations during the pharmaceutical technology assessment (PTA)…
Setting Priorities for Comparative Effectiveness Research: From Assessing Public Health Benefits to Being Open With the Public
Abstract (from Health Affairs): Medicine’s current evidence base is insufficient for many of the decisions made daily by clinicians, patients, purchasers, and policy makers. The Patient-Centered…
Comparative Effectiveness Research: Do Employers Care? What Will They Do? What About Productivity?
A survey by NPC and the Benfield Group found that one of the benefits employers are looking for from CER is more information about which treatments help with productivity.
Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research
Comparative effectiveness research (CER) has been heralded as a way to reduce health-care costs by determining which treatments provide the most benefit for the largest number of patients. This…
The Impact of Comparative Effectiveness Research on Health and Health Care Spending
Although health care stakeholders acknowledge that health care treatments can affect different segments of the patient population in different ways, early discussions focused on how comparative…
Employer Medication Adherence, Comorbidities, and Health Risk Impacts on Workforce Absence and Job Performance
While medication adherence is a critical element in reducing the impact of illness, employers should view it as just one of multiple components that are needed in strategic employee disease…
The Productivity Crisis in Pharmaceutical R&D
Advances in the understanding of the molecular basis of diseases have expanded the number of plausible therapeutic targets for the development of innovative agents in recent decades. However,…
The State of Comparative Effectiveness Research and the Environment for Decision-Making (2011)
Comparative effectiveness research (CER) has gained in national prominence in recent years through an infusion of federal funds and passage of the Patient Protection and Affordable Care Act (PPACA),…
Synergies at Work: Realizing the Full Value of Health Investment
According to this NPC-sponsored research, employers need a sound understanding of the value that a healthy employee population brings to their businesses. Synergies at Work: Realizing the Full Value…
The Patient-Centered Outcomes Research Institute Methodology Committee: Resource Guide
In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, broad health reform legislation that established the Patient-Centered Outcomes Research Institute (PCORI…
International Comparison of Comparative Effectiveness Research in Five Jurisdictions: Insights for the US
This article, published in the Ocotber 2010 issue of PharmacoEconomics, examines health technology assessments (HTA) in Canada, Sweden, Scotland, The Netherlands and Australia and identifies seven…